Schreck Ralf, Rapp Ulf R
Institut für Medizinische Strahlenkunde und Zellforschung, MSZ, Universität Würzburg, Würzburg, Germany.
Int J Cancer. 2006 Nov 15;119(10):2261-71. doi: 10.1002/ijc.22144.
Raf kinase signaling has been thoroughly investigated over the last 20 years. A-Raf, B-Raf and C-Raf, the 3 mammalian members of the Raf family, are involved in a variety of cellular processes such as growth, proliferation, survival, differentiation and transformation. The detection of B-RAF mutations in a wide variety of human cancers, the description of wildtype and mutant B-RAF as tumor antigens in melanoma and the promising outcome of clinical trials evaluating the Raf inhibitor Nexavar (Sorafenib, BAY 43-9006) have sparked a broad interest in the scientific community. After a short historical detour and an introduction into Raf kinase signaling, we are going to discuss here recent outcomes of Raf kinase research with respect to tumor formation and give an overview on current efforts to develop anticancer therapies interfering with aberrant Raf kinase signaling.
在过去20年里,Raf激酶信号传导已得到深入研究。Raf家族的3个哺乳动物成员,即A-Raf、B-Raf和C-Raf,参与多种细胞过程,如生长、增殖、存活、分化和转化。在多种人类癌症中检测到B-RAF突变,在黑色素瘤中将野生型和突变型B-RAF描述为肿瘤抗原,以及评估Raf抑制剂多吉美(索拉非尼,BAY 43-9006)的临床试验取得了令人鼓舞的结果,这些都引发了科学界的广泛兴趣。在进行简短的历史回顾并介绍Raf激酶信号传导之后,我们将在此讨论Raf激酶研究在肿瘤形成方面的最新成果,并概述目前开发干扰异常Raf激酶信号传导的抗癌疗法的努力。